Core Viewpoint - Zhejiang Kangnbei Pharmaceutical Co., Ltd. announced that its subsidiaries have been selected for the continuation procurement of certain drugs under the national organized procurement program, which is expected to positively impact the company's sales and market share [1][2]. Group 1: Selected Drugs Information - The company’s subsidiaries participated in the national organized procurement for the continuation of drugs, with 11 products including Tamsulosin Hydrochloride Sustained-Release Capsules and Piperacillin Sodium and Tazobactam Sodium for Injection being selected [1]. - The procurement period for the selected drugs will last until December 31, 2028, starting from the implementation of the selection results [1]. Group 2: Financial Impact - The total sales revenue from the selected drugs for 2024 is projected to be 385.29 million, accounting for 5.91% of the company's total revenue of 6.52 billion for the same year [2]. - For the first three quarters of 2025, the projected sales revenue from these drugs is 296.15 million, representing 5.95% of the company's revenue of 4.98 billion [2]. - The selected drugs are expected to maintain stable or declining prices, which will help the company expand sales and enhance brand influence [2].

Core Viewpoint - China National Pharmaceutical Modern (600420.SH) announced participation in the national centralized procurement for drugs whose agreements have expired, with 51 drugs from the company and its subsidiaries proposed for selection in the continuation procurement [1] Group 1: Procurement Details - The continuation procurement is organized for drugs from the first to eighth batches of national centralized procurement agreements that have expired [1] - The procurement cycle for the selected drugs will last from the execution of the selection results until December 31, 2028 [1] - The procurement office has not disclosed specific supply prices and quantities for the selected drugs [1] Group 2: Market Impact - Overall, the continuation procurement is expected to maintain price stability, with some drug prices potentially decreasing further [1] - Medical institutions will prioritize the use of the selected drugs during the procurement cycle, ensuring the completion of the agreed procurement volume [1] - The signing of sales contracts for the selected drugs is anticipated to solidify the company's existing market share and enhance its brand influence and market competitiveness [1] - The aforementioned matters are not expected to have a significant impact on the company's current operating performance [1]

Group 1 - The company, Baiyunshan, announced that its subsidiaries, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., participated in the national centralized procurement for the continuation of products whose agreements have expired [1] - A total of 24 products, including Cefuroxime Sodium Injection and Clindamycin Phosphate Injection, are proposed to be selected for this procurement, which is based on the demand reported by medical institutions [1] - The procurement cycle will last until December 31, 2028, starting from the actual execution date of the selected results [1] Group 2 - The total projected sales revenue for the selected products in 2024 is approximately RMB 798 million, accounting for 1.06% of the company's total revenue for that year [2] - For the first three quarters of 2025, the projected sales revenue is about RMB 550 million, representing 0.89% of the company's revenue during that period [2] - If contracts are signed and implemented, it will further increase product sales, enhance market share, and positively impact the company's brand image and future business development [2]

Core Viewpoint - ST Tian Sheng (002872.SZ) and its wholly-owned subsidiary Hubei Tian Sheng Pharmaceutical Co., Ltd. are participating in the national organized procurement for drugs whose agreements have expired, with some products expected to be selected in the upcoming procurement process [1] Group 1 - The company and Hubei Tian Sheng are involved in the national organized procurement for drugs as the agreement period has expired [1] - The proposed selection of the company's products in the procurement will potentially enhance sales scope, market share, and brand influence if contracts are signed and implemented [1]